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SUMMARY
A growing body of evidence implicates impairments in brain insulin signaling in early sporadic Alzheimer disease (sAD) pathology. However, the most widely accepted hypothesis for AD aetiology stipulates that pathological aggregations of the amyloid β (Aβ) peptide are the cause of all forms of Alzheimer's disease. Streptozotocinintracerebroventricularly (STZ-icv) treated rats are proposed as a probable experimental model of sAD. The current work reviews evidence obtained from this model indicating that central STZ administration induces brain pathology and behavioural alterations resembling those in sAD patients. Recently, alterations of the brain insulin system resembling those in sAD have been found in the STZ-icv rat model and are associated with tau protein hyperphosphorylation and Aβ-like aggregations in meningeal vessels. In line with these findings the hypothesis has been proposed that insulin resistance in the brain might be the primary event which precedes the Aβ pathology in sAD.
INTRODUCTION
Although neuropathologically Alzheimer's disease (AD) is characterized by the accumulation of extracellular plaques, consisting primarily of a low molecular weight amyloid-β (Aβ) peptide, and intracellular neurofibrillary tangles of aggregated hyperphosphorylated tau protein, it is well documented that AD is not a single entity. Currently, the leading hypothesis assumes that pathological assemblies of Aβ are the cause of all forms of AD, whereas other neuropathological changes, including tau hyperphosphorylation, are downstream consequences of pathological Aβ accumulation (Hardy and Selkoe, 2002) . However, the amyloid cascade hypothesis is consistent with only a very small proportion of all AD cases, that is those caused by missense mutations in three chromosomes (http://www.molgen.ua.ac.be/ADMutations/) leading to autosomal dominant familial AD with an early onset. In the great majority of AD patients disease is sporadic in origin (millions world-wide) with age and several susceptibility genes as risk factors, and is of late onset (Hoyer and Frölich, 2006) . A growing body of evidence implicates impairments in the brain insulin signaling pathway in sAD pathology (Frölich et al, 1998; Frölich, 2006, de la Monte and . Since insulin has been shown to affect both Aβ levels and tau hyperphosphorylation in the brain, this issue has recently emerged as a novel field of sAD ethiopathogenesis and therapy research (de la Hoyer, 2004) . Due to the developmentally specific nature of sAD, its early stages being clinically unrecognisable, and brain analysis being possible only post mortem (frequently in only the severe late stage cases), brain neurochemistry that characterizes the initiation of this disease in humans is mostly unknown. Experimental models of sAD may provide clues to early brain changes in this disorder. This review presents the information gained to date in the experimental rat model of sAD which has paved the way to the new hypothesis, the implications of which may provide novel ethiopathogenic and therapeutic approaches in sAD research.
INSULIN IN THE BRAIN
Until the last three decades, the brain has not been thought of as an insulin-sensitive organ. The first evidence arguing against this hypothesis was the detection of immunoreactive insulin in dog cerebrospinal fluid (Margolis and Altszuler, 1967) , suggesting that circulating insulin could cross the blood-brain barrier. The discoveries of insulin and insulin receptors (IR) in the brain that followed (Havrankova et al, 1978a,b) raised further questions about the origin of insulin in the brain, as well as physiological and pathophysiological role(s) of insulin and IR in this organ. An extensive review of the current knowledge of insulin and IR and their roles in the brain has been published previously (Hoyer and Frölich, 2006) , and will be presented briefly here for the purpose of comparison with the data from human and experimental models of sAD.
It is a common belief that in the mature adult brain the majority of insulin originates from the periphery; that is it is transported from the circulation after secretion from the pancreatic β-cells. The transport of insulin across the blood brain barrier (BBB) is mediated via a saturable transport mechanism for which regional specificity in transporter distribution and kinetics has been reported (Banks, 2004) . However, evidence has emerged that a smaller proportion of insulin is produced within the brain itself (Wozniak et al., 1993) . Insulin gene expression and insulin synthesis have been demonstrated in both immature and mature mammalian neuronal cells (Schechter et al. 1992; Schechter et al. 1996; Schechter and Abboud 2001) . In humans and in the chicken only one insulin gene is present, whereas in mice and rats insulin is produced by two independent genes that code for proinsulin I and II, both of which are localized to chromosome 1 (Todd et al. 1985) . Insulin-1 and -2 mRNA were found to be distributed in a highly specific pattern with the highest density in the pyramidal cells of the hippocampus and high densities in medial prefrontal cortex, the entorhinal and perirhinal cortices, the thalamus and the granule layer of the olfactory bulb, as well as the hypothalamus (Devaskar et al., 1994; Grünblatt et al., 2006) . Neither insulin mRNA nor synthesis of the hormone were observed in glial cells (Devaskar et al. 1994) . The release of insulin from brain synaptosomes is stimulated by glucose (Santos et al. 1999) .
Insulin signaling in the brain
Insulin in the brain binds to IRs which are abundantly but selectively distributed. Rodent studies have shown that the highest concentration of IRs is found in the nerve terminals of key brain regions, such as the olfactory bulb, hypothalamus, cerebral cortex, cerebellum and hippocampus (van Houten et al, 1979; van Houten et al, 1980; Unger et al, 1989; Abbott et al, 1999) . IR mRNA is abundantly present in neuronal somata (Schwartz et al, 1992) . The neuronal IR binds insulin in a highly specific and rapid manner (Raizada et al, 1988) . It has been hypothesized that the differing distribution patterns of insulin-1 and IRs in the brain may suggest that IRs in different brain regions may use insulin from different sources, either peripherally or locally synthesized, for cell-to-cell communication and neuronal signal transduction (Zhao et al. 2004 ). The IR is a tetramer composed of two extracellular α-subunits and two intracellular β-subunits. The neuronal (brain) IR differs from the peripheral IR in that both the α and β subunits have a slightly lower molecular weight, and the neuronal IR is not down-regulated by insulin, which otherwise activates a similar signalling cascade (Adamo et al, 1989; Heidenreich et al, 1983) . Binding of insulin to the IR α-subunit induces autophosphorylation of the β-subunit by phosphorylation of its intrinsic tyrosine residues 1158, 1162 and 1163, thus triggering tyrosine kinase activity (Fig. 1A ) (Combettes-Souverain and Issad, 1998) . The location of phosphotyrosinecontaining proteins corresponds to IR distribution (Moss et al, 1990) . The receptor's activation state is regulated by its phosphorylation state. Deactivation may be induced by the action of both phosphotyrosine phosphatase causing dephosphorylation of the β subunit (Goldstein, 1993) and by serine or threonine kinases causing phosphorylation at serine residues 1305 and 1306, and threonine residue 1348 respectively (Häring, 1991; Avruch, 1998) . Insulin binding to the IR activates two parallel functional signal transduction cascades; one acting through the phosphatidylinositol-3 kinase (PI3K) pathway, and the other acting through the mitogen activated protein kinase (MAPK) pathway (Johnston et al., 2003) . The former will be discussed later in the text. Briefly, tyrosine phosphorylation of IR β-subunits induces specific recruitment of proteins containing particular domains (SH2, PTB, etc.), amongst the most prominent of which are the proteins from the insulin receptor substrate family (IRS). It has been shown that IRS1 and the IR are co-expressed in particular brain regions, including the hippocampus (Baskin et al, 1994) . Upon IR activation, the IRS becomes phosphorylated on tyrosine residues and capable of recruiting various specific (e.g. SH2) domain-containing signalling molecules; among them PI3K which becomes phosphorylated and consequently activated (Johnston et al., 2003) . The activation of the PI3K pathway, in turn activates protein kinase B (Akt/PKB) (Fig. 1) . The activated Akt/PKB triggers glucose transporter (such as GLUT4) translocation and consequently increases cellular glucose uptake (Johnston et al., 2003; Vannucci et al., 1998) . Akt/PKB also phosphorylates (at the serine 9 residue) and consequently inactivates both α and β cytosolic forms of glycogen synthase kinase-3 (GSK-3) (Cross et al., 1995) . GSK-3 plays a key role in numerous cell functions, but only those that may be involved in sAD pathology will be briefly mentioned here. GSK-3α regulates the production of Aß peptides, the amyloid precursor protein (APP) derivatives (Phiel et al, 2003) . The promotion of APP secretion from the intracellular to the extracellular space and the inhibition of its degradation by insulin-degrading enzyme is mediated by insulin and the tyrosine kinase activity of the IR (Gasparini et al, 2001 ). Furthermore, insulin signaling via activation of PI3K regulates APP release into the extracellular space (Solano et al, 2000) . GSK-3β isoform is involved in tau-protein phosphorylation (Ishiguro et al., 1993) . Tauproteins belong to a family of microtubule-associated proteins that stimulate the generation and stabilization of microtubules within cells, and control axonal transport of vesicles (Stamer et al., 2002) . Accumulation of hyperphosphorylated tau protein leads to the formation of neurofibrillary tangles. The phosphorylation and dephosphorylation of the tau protein is regulated by several protein kinases, including GSK-3β, and by several protein phosphatases, including PTP-1, -2A, -2B (Ishiguro et al, 1992; . Prolonged exposure to insulin has been shown to induce down-regulation of glycogen synthase kinase-3ß activity and, thus, decreased phosphorylation of tau-protein (Cross et al, 1997; Hong and Lee, 1997 ).
Insulin's role in learning and memory
Evidence has been provided that brain insulin and the IR are functionally linked to improved cognition, in particular general and spatial memory, by up-regulation of insulin mRNA in the hippocampus and increased accumulation of the IR in hippocampal synaptic membranes (Zhao et al, 1999; for review Park, 2001; Zhao et al, 2004) . Recent in vivo evidence has demonstrated that the effect of intrahippocampal microinjection of insulin on spatial learning and memory in rats is dose-dependent, that is cognitive function is impaired with low insulin doses, unchanged with intermediate doses, and improved with high insulin doses (Moosavi et al, 2006) . Although the exact mechanism(s) by which insulin could affect learning and memory is unclear, several pathways have been suggested, for example those related to glucose metabolism and the modulation of neurotransmission by different neurotransmitters. The overlapping distributions of insulin, the IR and the insulin-sensitive glucose transporter (GLUT) isoforms support the hypothesis of insulin-stimulated glucose uptake in selective brain regions, the hippocampus in particular (Apelt et al, 1999; McEwen and Reagan, 2004) . Since hippocampal glucoregulatory activities contribute to cognitive function (Reagan, 2002) , insulin modulation of glucose metabolism in this structure appears to be one of the key components of hippocampal vulnerability. Additionally, insulin is likely to modulate memory via other molecular events, such as increasing the probability of inducing longterm amplification, a molecular model of learning, by promoting N-methyl-D-aspartate receptor conductance (Wang and Salter, 1994) , as reviewed elsewhere (van der Heide et al, 2006) . Insulin may also modulate cognitive functions via its effects on neurotransmission, e.g. low doses of insulin can reverse the amnestic effects of cholinergic blockade (Blanchard and Duncan, 1997) , and high levels of insulin reduce neuronal norepinephrine reuptake (Figlewicz et al, 1993) . Thus the data suggests that normal insulin and IR signaling is a prerequisite for normal learning and memory function.
AN EXPERIMENTAL RAT MODEL OF sAD: STREPTOZOTOCIN-INTRACEREBROVENTRICULARLY TREATED RATS
Given the complex nature of AD, it is difficult to establish an experimental animal model that would faithfully mimic the developmental pathology of this disease in humans. Frequently exploited are transgenic Tg2576 mice that over express the Swedish mutation of the human APP and demonstrate a progressive, age-related cortical and hippocampal deposition of Aβ plaques (Hsiao et al, 1996) . Transgenic Tg2576 mice however, represent a model of AD induced by gene manipulation, and therefore, are unlikely to be representative of the sporadic type of this disease. Given the presence of the IR and insulin, as well as the possibility of its synthesis in the brain, and of disturbed insulin signal transduction in human sAD (Hoyer and Frölich, 2006) , an experimental rat model was developed by using the drug streptozotocin (STZ).
STZ treatment
STZ (2-deoxy-2-(3-(methyl-3-nitrosoureido)-D-glucopyranose)) is a betacytotoxic drug which, following peripheral (parenteral) administration at high doses, selectively destroys insulin producing/secreting β cells in the pancreas, and causes type I diabetes mellitus in adult animals (Szkudelski, 2001) . Type II diabetes can also be induced in rats by parenteral injections of STZ on the day of birth, resulting in a mild basal hyperglycemia, an impaired response to the glucose tolerance test, and a loss of β GSK-3 plays a key role in numerous cell functions, but only those that may be involved in cell sensitivity to glucose, 10 weeks post-injection (Szkudelski, 2001) . Treatment with low to moderate doses of STZ in shortterm experiments causes insulin resistance (Blondel and Portha 1989 ) via a decrease in autophosphorylation (Kadowaki et al. 1984) and an increase in total number of IRs, but with little change in phosphorylated IR-β subunit (Giorgino et al. 1992) , and maintained insulin-immunoreactive cells in the pancreas generating a transient diabetes mellitus (Rajab et al. 1989; Ar'Rajab and Ahren 1993) . Considering the presence of insulin (from both periphery and brain) and IRs in the brain, an experimental rat model was developed by using STZ applied intracerebroventricularly (icv) in doses of up to 100 times lower (per kg body weight /b.w./) than those used peripherally to induce an insulin resistant brain state (Nitsch and Hoyer, 1991; Duelli et al, 1994; Lannert and Hoyer, 1998) . Central STZ administration caused neither systemic metabolic changes nor diabetes mellitus. In the past 17 years, since the first literature report of central STZ application, STZ has been administrated mostly in doses ranging from 1-3 mg/kg b.w., injected 1-3 times, either unior bi-laterally into the lateral cerebral ventricles (Table 1) . Identical biochemical changes were found in the left and right striatum after administration of STZ to the right lateral cerebral ventricle only (Salkovic et al., 1995) , suggesting that STZ-icv induced effects are not related to the direct non-specific toxic effect of STZ at the site of drug administration and that differing effects following uni-or bi-lateral application of STZ are not to be expected. In some of the experiments however, a wide variation in the susceptibility of individual animals has been demonstrated as a characteristic feature of STZ-icv treatment (Blokland and Joles, 1993; Prickaerts et al., 2000) . Most experiments with STZ-icv applications used Wistar rats, with only a few utilising the Sprague-Dawley (Shoham et al., 2006) or Lewis strains (Prickaerts et al., 2000) . Male animals were used in all experiments. Recently, bilateral intra-cortical administration of low STZ doses (40 µg/kg) to three-dayold rat pups has been reported de la Monte et al., 2006) .
STZ mechanism of action
The mechanism of central STZ action and its target cells/molecules have not yet been clarified but a similar mechanism of action to that in the periphery has been recently suggested. In the periphery, STZ selective β cell toxicity results from the drug's chemical structure which allows it to enter the cell via the GLUT2 glucose transporter. The predominant site of GLUT2 localization is the pancreatic β cell membrane (Szkudelski, 2001) . In vitro studies have also demonstrated that GLUT2 itself is a key target molecule for STZ as the drug reduces GLUT2 protein expression in a concentration-dependent manner (Gai et al, 2004) . GLUT2 may also be responsible for the STZ induced effects in the brain as GLUT2 also is reported to have regional specific distribution in the mammalian brain (Brant et al, 1993; Leloup et al, 1994; Ngarmukos et al, 2001; Arluison et al, 2004a; Arluison et al, 2004b) . The neuronal localization of GLUT2 is relatively similar to that of glucokinase (GLUT2 coupled with glucokinase participate in the glucose sensing mechanism of β-cells), supporting the hypothesis that GLUT2 is expressed by brain neurons involved in glucose sensing (Arluison et al, 2004a; Arluison et al, 2004b) . However, since GLUT2 localization in the brain does not entirely parallel that of glucokinase at the quantitative level (Li et al. 2003) , participation of GLUT2 in functions other than glucose sensing in the brain has been suggested (Arluison et al. 2004b; Arluison et al. 2004a) . Following peripheral administration STZ causes alkylation of β-cell DNA which triggers activation of poly ADP-ribosylation, leading to depletion of cellular NAD+ and ATP (Szkudelski, 2001) . Decreased levels of ATP have also been reported following STZ-icv treatment (Nitsch and Hoyer 1991; Lannert and Hoyer 1998) . The chemical structure of STZ also suggests this compound may produce intracellular free radicals, nitric oxide (NO) and hydrogen peroxide (Szkudelski, 2001) ; indeed evidence of increased oxidative stress has been found in the brain of STZ-icv treated rats (Table 1) . Possible STZ effects on insulin producing/secreting and insulin sensitive cells within the brain will be discussed later in the text. The exact intracellular effects stimulated by icv administration of STZ are likely to be elucidated only following identification of the brain cells targeted by this compound.
NEUROCHEMICAL, STRUCTURAL AND BEHAVIORAL CHANGES IN THE STZ-ICV RAT MODEL

Glucose/energy metabolism
Glucose is the principal source of energy production in the brain, and undisturbed glucose metabolism is critical for normal functioning of this organ. Brain glucose, and its metabolism, has been investigated from 3 weeks following STZ-icv administration (Table  1) , where concentrations of glucose and ADP, as well as glycogen levels, were increased in the cerebral cortex (Nitsch and Hoyer 1991) , and glucose utilization was significantly decreased (44%) (Pathan et al, 2006) . Further, 6 weeks following STZ-icv treatment, reduced glucose utilization (up to 30%) was found in 17 of 35 brain areas, particularly the frontal, parietal, sensory motor, auditory and entorhinal cortex and in all hippocampal subfields (Duelli et al. 1994 ). In addition, significant decreases in activities of glycolytic key enzymes were found in the brain cortex and hippocampus 3 and 6 weeks post-STZ-icv administration (Plaschke and Hoyer 1993) resulting in diminished concentrations of the energy-rich compounds ATP and creatine phosphate (Nitsch and Hoyer 1991; Lannert and Hoyer 1998) . This fall in cerebral ATP, GTP and creatine phosphate levels was significantly improved by 40-day subcutaneous treatment with estradiol or intraperitoneal injection with the antioxidant coenzyme Q10, in parallel with the initial administration of STZ (Lannert et al., 1998; Ishrat et la., 2006) . Decreased glucose utilization in hippocampal and cortical tissue was significantly, and dose-dependently, increased by 2-week long oral treatment with the peroxisome proliferator activated γ receptor (PPARγ) agonist, pioglitazone, applied from 5 days before to 9 days after the STZ-icv treatment (Pathan et al., 2006) . PPARγ agonists are approved as oral hypoglycemic agents used in the treatment of insulin resistance in type 2 diabetes, but have also demonstrated some neuroprotective effects (Santos et al., 2005; Bordet et al., 2006) .
Cholinergic transmission
Investigations of cholinergic transmission in STZ-icv treated rats are important as abnormalities in the central cholinergic system affect learning and memory (Spencer and Lal, 1983) . A decrease in choline acetyltransferase (ChAT) activity has been consistently found in the hippocampus of STZ-icv treated rats as early as 1 week following drug treatment and is still present 3 weeks post-injection (Hellweg et al, 1992; Blokland and Jolles, 1993; Blokland and Jolles, 1994; Prickaerts et al, 1999; Terwel et al, 1995) (Table  1 ). This is followed by a significant increase in acetylcholinesterase (AChE) activity (Sokusare et al, 2005; Ishrat et al, 2006) . A decrease in hippocampal ChAT activity was completely prevented by 2-weeks of orally administered acetyl-L-carnitine, which acts by enhancing the utilization of alternative energy sources Terwel et al., 1995) . Chronic administration of cholinesterase inhibitor drugs reduced AChE activity in a dose dependent manner, in STZ-icv treated rats regardless of whether treatment began 1 week prior to, in parallel or 13 days after STZ-icv administration (Sonkusare et al., 2005; Shoham et al, 2006) . AChE activity was inhibited in the cortex but not in the hippocampus (Shoham et al, 2006) , and concomitant administration with the calcium channel blocker, lercanidipine, potientated a decrease in AChE activity (Sonkusare et al., 2005) . Changes in both ChAT and ACheE in the hippocampus were prevented by chronic intraperitoneal treatment with the antioxidant coenzyme Q10 (Ishrat et al., 2006) . Intra-cortical administration of STZ to rat pups was followed by reduced expression of ChAT and increased expression of the AChE gene, a response which could not be prevented by any of the three subtypes of PPAR agonists de la Monte et al., 2006) .
Oxidative stress
Evidence of increased oxidative stress has been found in whole brain homogenates in particular brain regions of STZ-icv treated rats (Table 1) . Estimations of oxidative stress induced by STZ-icv treatment commonly ultilise the measurement of malonaldehyde levels (MDA), a product of lipid peroxidation used as an indicator of free radical generation, and glutathione levels, an endogenous antioxidant that scavenges free radicals and protects against oxidative stress, or immunohistochemically for nitrative stress. Significant elevations of MDA levels and decreased glutathione levels have been found in the brain of STZ-icv treated rats (Sharma and Gupta, 2001a; Sharma and Gupta, 2002; Ishrat et al, 2006; Pathan et al, 2006) . A progressive trend towards oxidative stress has been found 1, 7 and 21 days following STZ-icv administration (twice 3mg/kg injections) to 4 month old rats (Sharma and Gupta, 2001a) . Oxidative stress was found also in the brain of 1 year old rats, 3 weeks following a lower single STZ-icv dose of 1.5 mg/kg (Ishrat et al., 2006) . STZ-icv generates NO (Szkudelski, 2001) , and oxidative-nitrative stress was found 1 and 8 weeks following a single 3mg/kg STZ-icv dose (Shoham et al., 2006) . Nevertheless it appears that generation of NO by NO synthase is not involved since inhibition of this enzyme has not prevented STZ-induced responses (Prickaerts et al., 2000) . Chronic treatment with the antioxidant coenzyme Q10 starting from the day of STZ-icv treatment significantly reduced all parameters of oxidative stress (Ishrat et al., 2006) . A similar effect has been reported for other antioxidants (Sharma and Gupta, 2001a; .
Morphology
STZ-icv administration has been associated with certain brain morphological changes in the brain as early as 1 week following a single drug dose (Shoham et al., 2006) , and in both ≥1 year and 4 month old rats (Terwel et al., 1995; Prickaerts et al., 2000; Shoham et al., 2003; 2006) (Table 1) . Glial fibrillary acidic protein (GFAP), a marker of astrogliosis, a stereotypic reaction of astrocytes to neuronal damage (Prickaerts et al., 1999) , has been found to be increased in both brain homogenates and tissue sections (Prickaerts et al., 1999; 2000) . Increased GFAP immunocytochemical staining was mainly located in periand paraventricular regions including the septum, fornix and fimbria, striatum and hippocampus, suggesting that altered hippocampal function could result from an impaired innervation and direct damage to this region (Prickaerts et al., 2000; Shoham et al., 2003) . Inflammatory processes and myelin and axonal neurotoxicity has been reported following STZ-icv treatment. Severely affected STZ-icv treated rats had not only astrogliosis, but also extensive cell loss, inferred from the increase in the volume of the ventricular system (Prickaerts et al., 2000; Shoham et al., 2003) . Interestingly, one week after a single STZicv 3mg/kg dose, no change in the number or morphology of cholinergic neurons was detected in the basal forebrain nuclei, medial septum, diagonal band or the nucleus basalis magnocellularis and there was no change in the density of cholinergic terminals in the hippocampus (Shoham et al., 2006) . Not withstanding, AChE activity was increased, a phenomenon the authors explained as a reduction in synaptic function associated with increased GFAP expression in activated astrocytes. Astrogliosis was prevented by a chronic treatment with ladostigil, a cholinesterase and monoamine oxidase-B inhibitor with neuroprotective effects (Shoham et al., 2006) . At the ultrastructural level, 3 weeks following STZ-icv administration a significant enlargement of the trans-Golgi segment in the rat cerebral cortex was found, which did not resemble the Golgi atrophy found in the brain of sAD patients, but the authors suggested that considering the proamyloidogenic processing of beta-amyloid precursor protein may occur preferentially in the trans-Golgi segment, the observed early response of neuronal ultrastructure to desensitisation of the IR may predispose cells to form Aβ-amyloid deposits (Grieb et al., 2004) . Differences in morphological changes in the brain in human sAD and the STZ-icv rat model could be related to direct STZ actions.
Reduced expression of neuronal-and oligodendroglia-specific genes and increased expression of genes encoding GFAP and microglia-specific proteins were also found in rat pups administered with STZ intra-cortically (STZ-ic) . Some authors have suggested the hypoplasia and degeneration of the cerebellum found in STZ-ic treated rat pups, unlike findings in AD, are related to the early postnatal development of the cerebellum in rodents. PPAR agonists produced receptor subtype-and regiondependent positive therapeutic effects in STZ-ic treated pups with PPAR-δ agonists being the most effective (PPAR δ>α>γ subtype effectiveness) in preservation of hippocampal and temporal lobes (de la .
Learning and memory
STZ-icv treated rats consistently demonstrate deficits in learning, memory, and cognitive behaviour (Table 1) . Cognitive deficits are long-term and progressive, observed as early as 2 weeks after STZ-icv administration and are maintained up to 12 weeks post treatment (Lannert and Hoyer, 1998; Salkovic et al., 2006 , Shoham et al., 2006 Grünblatt et al, 2006) . They are found regardless of age in both 1-2 year and 3-month old rats, and also after either a single 1 or 3mg/kg injection or multiple 1mg/kg STZ-icv injections (Mayer et al, 1990; Pathan et al, 2006; Lannert and Hoyer, 1998; Weinstock and Shoham, 2004; Salkovic-Petrisic et al., 2006 , Shoham et al., 2006 Grünblatt et al, 2006) , although some STZ-icv dose-dependency has been suggested with lower STZ doses inducing less severe cognitive deficits (Blokland and Joles, 1994; Prickaerts et al., 2000; Grünblatt et al, 2006) . The correlation between spatial discrimination performance in the Morris task and the decrease in hippocampal ChAT activity which resembles the relationship between cognitive and biochemical cholinergic changes observed in AD has been found in STZ-icv treated rats (Blokland and Jolles, 1993; Blokland and Jolles, 1994) . However, results of the effectiveness of chronic acetyl-L-carnitine treatment in the prevention of hippocampal ChAT activity and abolishing memory deficits in the Morris water maze swimming (MWM) test, are inconsistent (Terwel et al., 1995) . Interestingly, it has also been demonstrated that STZ-icv induced development of reactive gliosis and oxidative stress 1 week post-treatment, preceded the induction of memory deficits at 3 weeks post-treatment (Shoham et al, 2006, Sharma and Gupta, 2001a) , where no signs of neuronal damage or any reduction in specific cholinergic markers were detected in the cortex or hippocampus (Shoham et al., 2006) . Although the exact mechanism by which STZ-icv treatment damages cognitive function remains unknown, all changes discussed above; energy deficits, reduced activity of choline acetyltransferase (cholinergic deafferentiation), induction of oxidative stress and direct neurotoxic damage found in the fornix, anterior hippocampus and periventricular structures, may form the biological basis for the marked reduction in learning and memory capacities. Concordingly, memory deficits were reported to be prevented by chronic treatment with several types of drugs with differing mechanisms of action (as reviewed by Weinstock and Shoham, 2004) ; (I) drugs generating alternative energy sources such as acetyl-L-carnitine ; (II) cholinesterase inhibitors such as donepezil and ladostigil (possessing also monoamine oxidase B inhibition and neuroprotective activity which also prevent gliosis and oxidative stress (Sonkusare et al., 2005; Shoham et al., 2006) ; (III) estradiol which prevents reduction in cerebral ATP (Lannert et al., 1998) ; (IV) antioxidants such as melatonin, resveratrol and coenzyme Q10 which prevent an increase in free radical generation (Sharma and Gupta, 2001b; Ishrat et al., 2006) . Treatment with the NO synthase inhibitor L-NAME had no protective effect on cognitive deficits in STZ-icv treated rats (Prickaerts et al., 2000) .
BRAIN INSULIN AND THE IR SIGNALING CASCADE IN STZ-ICV RAT
Although alterations of the brain insulin system are the focus of human sAD research (Hoyer and Frölich, 2006) , investigations in experimental models of this neurodegenerative disorder are rare, particularly those exploiting central STZ administration (Table 2 and 3) . We have previously reported changes in the brain insulin and tau/Aβ system following the bilateral application of a single or multiple 1mg/kg STZ dose into the lateral cerebral ventricles of adult ≥3 month old rats (Salkovic-Petrisic et al., 2006; Grünblatt et al., 2004 , Grünblatt et la., 2006 and the group of de la Monte et al. has reported changes in the brain insulin system following bilateral intra-cerebral 40µg/kg STZ dose to three-day-old rat pups. Since only the abstract of a Chinese paper is available regarding brain immunohistochemical analysis of tau protein and Aβ expression, 3 weeks following STZ-icv treatment (Chu and Quian, 1995) , there is little data for a reliable interpretation of their findings.
In STZ-icv treated adult rats region-specific alterations of the brain insulin system (including insulin, the IR and downstream IR signaling cascade) were identified, and these changes are progressive beyond the STZ-icv treatment period (Table 2) (Salkovic-Petrisic et al., 2006; Grünblatt et al., 2006) . A decrease in the expression of the insulin gene 1 and 2, as well as the IR gene, was identified in the hippocampus and frontoparietal cortex 12 weeks following drug treatment. The IRβ protein was decreased in the frontoparietal cortex and hypothalamus, but the levels of phosphorylated IRβ (p-IRβ) were increased and tyrosine kinase activity was unchanged in these regions, whereas in the hippocampus IRβ protein levels were decreased, but p-IRβ levels, as well as tyrosine kinase activity, were increased. Downstream from the PI3-K signaling pathway, hippocampal Akt/PKB remained unchanged at 4 weeks and decreased by 12 weeks post-treatment, whereas in the frontoparietal cortex Akt/PKB expression was decreased 4 weeks and increased by 12 weeks post STZ-icv treatment. Total GSK-3 levels were unchanged whereas the p-GSK-3/GSK-3 ratio in the hippocampus was decreased 12 weeks following STZ-icv treatments, suggesting a change in GSK-3 activity. In line with this finding, as a downstream target of the IR signaling cascade, increase in the expression of tau protein and the p-tau/tau ratio were found in the hippocampus 4 and 12 weeks following STZ-icv treatment, respectively, and Aβ-like aggregates were absent 4 weeks following drug treatment, but were found in leptomeningeal capillaries 12 weeks post STZ-icv treatment (Table 3) .
Although the investigated parameters in the brain and the direction of changes identified following the intra-cortical (ic) application of STZ (decreased mRNA expression of insulin, the IR and IGF-1R, decreased pGSK-3/GSK-3 ratio) are similar to those induced by STZ-icv administration (Table 2 and 3) de la Monte et al., 2006) , the results are not quite comparable for several reasons; (I) Intra-cortical administration of STZ in the rat pups could be expected to induce more non-specific localized tissue damage than administration of STZ into the cavity of the lateral cerebral ventricles of adult rats. (II) Sensitivity of brain neurons to STZ toxic effects could be expected to differ in the three-day-old pups and adult or old rats, at least due to differences in the DNA excision repair processes known to be important for STZ intracellular toxicity (Szkudelski, 2001) . (III) Strain differences in the susceptibility to STZ-induced diabetes have been reported (Rodrigues et al., 1997) , and two different rat strains were used in icv treatment of adult/old rats (Wistar strain, most frequently used in other STZ-icv treatment experiments) and ic treatment of rat pups (the Long Evans strain is generally used for the investigation of retinal complications of diabetes (Puro, 2002) . (IV) Brain regions investigated were not completely comparable; frontoparietal cortex, hippocampus and hypothalamus in STZ-icv, and temporal lobe, cerebellum and hypothalamus in STZ-ic treatment. The region-specific STZ-induced changes in the brain, including the difference in changes observed in the hippocampus in comparison with the cerebral cortex (SalkovicPetrisic et al., 2006) , could be masked in STZ-ic treated pups where temporal lobe (including hippocampal formation) was biochemically analysed. (V) Time dependency of changes could not be concluded from experiments with STZ-ic treated rat pups as these were measured at only a single post-treatment period of 4 weeks (de la or three post-treatment periods were investigated (7, 14 , and 21 days) but results were reported only for the 14-day period . Some changes were not observed at 4 weeks but appeared 12 weeks following STZ-icv treatment, like those of tau protein and Aβ (Salkovic-Petrisic et al., 2006) , but were already present two or four weeks after STZ-ic treatment de la Monte et al., 2006) (Table 3) . Some additional parameters of tau protein and the Aβ system (tau and APP mRNA expression) were investigated in STZ-ic treated pups with a discrepancy between significantly decreased tau mRNA and unchanged tau protein expression observed in the hypothalamus (de la . Modest data has been reported regarding the therapeutic effects of drugs on brain insulin system alterations induced by central STZ application, i.e. only the effects of PPAR agonists in STZ-ic treated rat pups were investigated (de la . These drugs demonstrated some therapeutic effects with respect to the insulin/IR signaling cascade dysfunction, but it is import to note that the effects were region-and PPAR subtype-specific. Not all PPAR-subtype agonists showed positive effects on STZ-induced damage and some of the alterations (insulin mRNA and p-GSK-3/GSK-3 ratio) did not respond to any of the PPAR-subtype agonists used (Tables 2 and 3) . Although the PPAR-δ subtype agonists were the most effective (this subtype was found to be most abundant both in rat and human brain) (de la , they were incapable of normalizing the changes to APP mRNA in the temporal lobe in contrast to the PPAR-α and -γ subtype agonists. Also, it has to be kept in mind that the positive therapeutic effects of PPAR agonists in STZ-ic treated pups on IR dysfunction (as well as on cholinergic transmission and neuronal damage), were obtained 4 weeks after a single intraperitoneal injection given on the same day as STZ. Evidence for the entry of these PPAR agonist substances through the blood brain barrier, which is of vital importance for their effects within the brain after only a single intraperitoneal injection, has not been provided by authors. Further experimentation is needed to clarify the meaning of these findings in respect to the mechanism of PPAR agonists since the positive therapeutic effects of treatment with the chronic PPAR-γ agonist rosiglitazone (which probably does not pass the blood brain barrier in a significant amount) (Pedersen and Flynn, 2004) on cognitive deficits in both humans with sAD and transgenic Tg2576 Alzheimer mice, are suggested to be related to an improvement of peripheral insulin resistance which positively affects cognition (Watson et al., 2005; Pedersen et al., 2006; Landreth, 2006) . Such a mechanism does not seem likely in 3 day-old rat pups which do not develop peripheral insulin resistance since decreased blood glucose levels were found 14 days following the STZ-ic administration .
INSULIN RESISTANT BRAIN STATE AS A PROBABLE TRIGGER FOR sAD PATHOLOGY
Convincing evidence indicates that central STZ administration induces alterations resembling those found in sAD patients (Hoyer and Frölich, 2006; Cole and Frautschy, 2006; Qiu and Folstein, 2006; Watson and Craft, 2006; Wada et al., 2005) . Similarities between human sAD and the STZ-icv model have been noted at three different levels; (I) biochemically, in the region-specific decrease in glucose utilization, reduction in cholinergic transmission and activation of the markers of oxidative stress damage, (II) morphologically, in neuronal damage and loss in hippocampal volume and associated structures accompanied by astroglyosis and neuronal inflammation, and finally, (III) behaviourally, manifested as progressive learning and memory deficits. However, regardless of these similarities, none of these biochemical alterations were able to provide a missing link that could connect all these changes to give a clue to the primary event which could initiate the pathological hallmarks of sAD, hyperphosphorylated tau protein in neurofibrillary tangles and aggregated Aβ peptide in amyloid plaques. Region-specific and, for some parameters, time-progressive, changes of the rat brain insulin system following STZ-icv treatment seem to be the missing link. Disturbances in insulin action, IR function and downstream signaling pathways have been found post mortem in the brain of sAD patients (Hoyer and Frölich, 2006; Cole and Frautschy, 2006; Qiu and Folstein, 2006; Watson and Craft, 2006; Wada et al., 2005) , suggesting a condition of brain insulin resistance, very similar to that found in STZ-icv and STZ-ic treated rats (Salkovic-Petrisic et al., 2006; Grünblatt et al., 2006 , de la Monte et la., 2006 .
The STZ-icv treated rat model has provided additional evidence that a progression of the brain insulin resistant state over time leads to Alzheimer-like tau protein and Aβ pathology. Three major questions arise from this hypothesis; (1) what could trigger the brain insulin resistant state in sAD and at which point in the insulin/IR/downstream signaling cascade; (2) how is the brain insulin resistant state connected to pathological changes in the brain; and (3) what are the implications of this hypothesis in relation to the drug treatment of sAD?
One of the main risks for sAD is aging, associated with increased cortisol action due to a shift in the hypothalamic pituitary-adrenal (HPA) axis to an increased basal tone (Cizza et al., 1994 , for review Hoyer, 2004 , frequently reported in AD patients (Raber, 1998) . Cortisol may be a candidate for compromising the function of the neuronal IR via its dysregulation of the phosphorylation site of tyrosine residues in the receptor, and noradrenaline (found increased in cerebro-spinal liquid in sAD patients) may desensitise the neuronal IR by phosphorylation of serine/threonine residues (Fig. 1B) (Häring et al., 1986; Giorgino et al., 1993 , reviewed by Hoyer, 2004 . Desensitisation of the IR in sAD is suggested by findings of up-regulated IR density associated with reduced activity of IR tyrosine kinase . This point seems to be the only major difference between sAD and the STZ-icv rat model regarding the brain insulin system. Human data contradicts the findings of decreased or unchanged expression of the IRβ subunit, and the increased or unchanged expression of the tyrosine-phosphorylated IRβ subunit and tyrosine kinase activity seen in the STZ-icv model (Grünblatt et al., 2006) . However, this inconsistency could be related to the possible peripheral (e.g. glucocorticoid-induced) origin of the neuronal IR alterations in sAD and its lack in STZ-icv treated rats in which direct STZ-induced damage could be involved instead. On the other hand, data from STZicv model studies may point to an imbalance between the IR tyrosine phosphorylation and dephosphorylation under pathological conditions. This is in agreement with a generally known phenomenon of insulin receptor signaling dysfunction (i.e. an insulin resistant state) which may be caused when tyrosine phosphorylation, and/or when tyrosine dephosphorylation fails (Goldstein, 1993) , and/or when serine/threonine phosphorylation is increased and maintained at a high level (Häring, 1991; Avruch, 1998) as induced by the cytokine, tumor necrosis factor-α (Hotamisligil et al., 1994) . There is some evidence that failing receptor dephosphorylation may inhibit autophosphorylation activity (Lai et al., 1989) and that with time, tyrosine-phosphorylated IRs become inaccessible to phosphatases, therefore allowing persistence of tyrosine kinase activity (Paolini et al., 1996) . The activity of the protein tyrosine phosphatase (PTP) subtype 1B known to negatively regulate the function of the IR has not been particularly investigated in AD, but the likelihood of a decrease in function cannot be ruled out. Namely, IR autophosphorylation/dephosphorylation has been reported to be mediated by reactive oxygen species; ie. exposure to hydrogen peroxide could lead to oxidative activation of IR tyrosine kinase activity and oxidative inactivation of PTP (Droge, 2005) . STZ generates reactive oxygen species (Szkudelski, 2001) , and similarly aging and AD are associated with oxidative stress in the brain (Barja, 2004) . However, increased IR tyrosine activity does not necessarily lead to increased IR signal transduction throughout the cell, if intracellular downstream pathway signaling elements are affected, which is the case both in the animal model (Fig. 1B) (Salkovic-Petrisic et al., 2006; Lester-Coll et al., 2006) and in humans (Hoyer and Frölich, 2006) . Interestingly, the activity of the PTP enzyme was found to be regulated by insulin (Kenner et al. 1993) , and the activity of another protein phosphatase subtype, PP2A, has been found largely decreased in the mouse brain 3 days following peripheral STZ administration (Clodfelder-Miller et al., 2006) , but also in the human AD brain (Gong et al., 1995) . PP 2A and 2B are involved in phoshorylation/dephosphorylation regulation of tau protein (Gong et al., 1994a,b) . Thus, insulin resistant brain state, via IR signaling pathway dysfunction, may with time lead to the tau hyperphosphorylation directly through the PI3-GSK-3β pathway, or through the PP 2A pathway. Importantly, the PI3-GSK-3α pathway may also lead to Aβ pathology, as demonstrated in STZ-icv adult rats (Salkovic-Petrisic et al., 2006) and STZ-ic rat pups (Fig. 1B) , due to insulin-dependent production of APP derivatives, β-amyloid peptides (Phiel et al., 2003) . The time-dependent development of Aβ pathology has been clearly shown in the STZ-icv rat model with no pathological signs visible 4 weeks following STZ-icv treatment, and Aβ-like intracellular aggregates are visible 12 weeks afterwards (Salkovic-Petrisic et al., 2006) . This is in agreement with what has been recently proposed, namely that intracellular, rather than extracellular accumulation of β-amyloid is an initiating factor in the pathogenesis of AD (Oddo et al., 2003) . Low brain insulin levels reduce the release of Aβ from intracellular compartments into extracellular compartments where clearance is believed to occur. On the other hand, once generated, both derivatives of APP, ß-amlyoid (1-40) and ß-amlyoid (1-42) decrease the affinity of insulin for its receptor, resulting in reduced receptor autophosphorylation (Xie et al., 2002) , closing the circle back to IR signaling dysfunction. Although insulin protein concentration in the brain has not been measured directly in STZicv (ic) rats, it could be assumed that brain-derived insulin formation is reduced according to the downregulation of insulin mRNA expression both in animals (Grünblatt et al., 2006; Lester-Coll et al., 2006) and humans (Steen et al., 2006) . However, this may be compensated by peripherally formed insulin, due to undisturbed pancreas function after central STZ administration , as the main source of brain insulin is the pancreas, assuming that the pathobiochemistry induced after STZ-icv injection, is mainly due to dysfunction of the IR and downstream signalling. Data from sAD post mortem studies have demonstrated stronger insulin-immunoreactivity in neocortical pyramidal neurons but unchanged insulin and c-peptide biochemical levels compared to the age-matched controls .
Convincing evidence indicates that central STZ administration induces brain pathology and behavioural alterations resembling those found in sAD patients. Additionally, alterations of the brain insulin system found in this experimental model support the hypothesis that central insulin resistance might be the primary event which precedes Aβ pathology in sAD. Further studies are necessary to clarify this issue and its implications in relation to the drug treatment of sAD. Giorgino F, Chen JH, Smith RJ (1992) Fig 1. Brain insulin receptor signaling cascade in physiological conditions (A) and in the insulin resistant brain state (B) induced by the streptozotocinintracerebroventricular treatement. IR -insulin receptor; IGF-1R -insulin-like growth factor-1 receptor; TK -tyrosine kinase; IRS -insulin receptor substrate; MAP-Kmitogen activated protein kinase; PI3-K -phosphatidylinositol-3 kinase; Akt/PKBprotein kinase B; GSK-3 -glycogen synthase kinase-3; GSK-3-P -phosphorylated glycogen synthase kinase-3; APP -amyloid precursor protein; Aβ -amyloid beta; tautau protein; tau-P -phosphorylated tau protein; sAD -human sporadic Alzheimer's disease; STZ-icv -streptozotocin-intraverebroventricularly treated rats. Number of reference in brackets: (1) Salkovic-Petrisic et al., 2006 ; (2) Plaschke and Hoyer, 1993; (6) Duelli et al., 1994; (7) Lannert and Hoyer, 1998; (8) Pathan et al., 2006; (9) Grünblatt et al., 2004; (10) Lackovic and Salkovic, 1990; (11) Sharma and Gupta, 2001; (12) Pathan et al., 2006; (13) Shoham et al., 2006; (14) Ishrat et al., 2006. 
